RT Journal Article
SR Electronic
T1 Preference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2177
VO 40
IS Suppl 56
A1 Job van der Palen
A1 Thomas Ginko
A1 Axel Kroker
A1 Paul van der Valk
A1 Martijn Goosens
A1 Laura Padulles
A1 Beatriz Seoane
A1 Ludmyla Rekeda
A1 Esther Garcia Gil
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P2177.abstract
AB Introduction: Treatment outcomes in COPD depend on patient preference and satisfaction with their inhaler and inhaler technique. Patients often use their inhaler incorrectly, making critical errors that mean they get no drug or a suboptimal dose, leading to under-treatment of their disease.Aims: To investigate patient preference, satisfaction and critical errors with Genuair® vs HandiHaler® after 2 weeks of daily use.Methods: This was an open-label, randomised, cross-over, multicentre study in patients with COPD. Patients inhaled placebo through Genuair® and HandiHaler® daily for 2 weeks in addition to their current medication. The primary endpoint was the percentage of patients who preferred Genuair® after 2 weeks. Additional endpoints for each inhaler were overall patient satisfaction on a scale of 1 (very dissatisfied) to 5 (very satisfied), percentage of patients making ≥1 critical errors, and willingness to continue using each inhaler rated from 0 (not) to 100 (definitely). Data were analysed using Mainland-Gart's test or ANOVA.Results: The ITT population included 105 patients. Assessments at 2 weeks are shown in the table.View this table:Conclusions: Genuair® was associated with higher patient preference, satisfaction and fewer critical inhaler errors vs HandiHaler®.This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc., New York, USA.